Parallax Volatility Advisers L.P. raised its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) by 105.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,988 shares of the biotechnology company’s stock after acquiring an additional 26,736 shares during […]
StockNews.com initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a report published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock. A number of other research firms also recently commented on MRTX. SVB Leerink reaffirmed a market perform rating and issued a $58.00 target price (down previously […]
StockNews.com initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note released on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock. Several other research firms have also commented on MRTX. Morgan Stanley lowered their price target on shares of Mirati Therapeutics from $42.00 to $37.00 and […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) has been assigned an average recommendation of “Hold” from the sixteen brokerages that are currently covering the company, MarketBeat Ratings reports. Twelve investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price […]
StockNews.com assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a report published on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. MRTX has been the topic of several other reports. Bank of America reduced their target price on Mirati Therapeutics from $54.00 to $46.00 in a […]